Clinical Trial Update: A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial updating on trastuzumab emtansine in HER2-overexpressing solid tumors has completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Cholangiocellular Carcinoma
• Pancreatic Cancer

Drugs mentioned

• Trastuzumab emtansine (ado-trastuzumab emtansine)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Bladder Cancer, Pancreas Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-08-28